Clinical Trial Update: GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and tolerability of adding oral tesaglitazar to insulin therapy in patients with Type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED